By The Life Science Report

Source: Streetwise Reports   11/01/2017

An analysis of this company’s quarterly update highlights a pipeline studded with candidates targeting neurological indications.

In an Oct. 25 research report, H. C. Wainwright analyst Andrew Fein outlined the high points of Biogen Inc.’s (BIIB:NASDAQ) quarterly earnings update, noting that a “buzz” surrounds Spinraza but that his firm maintains its “long-standing focus on the AD [Alzheimer’s disease] franchise.”

Fein listed four takeaways from the company’s quarterly report:

• Multiple sclerosis “remains the main cash source for the company, despite a negative impact from Ocrevus”
• “Strong ex-U.S. adoption” of Spinraza, used to treat spinal muscular atrophy, “drove current quarter-to-quarter growth”
• “Renegotiation of the agreements with Eisai Inc. (ESALF:OTCPK; not rated) and Neurimmune (private), along with Eisai’s option-in on aducanumab, signaled Biogen’s (and Eisai’s) conviction behind the program”
• “Continued advancement and expansion of its neurology pipeline with enhanced ASO and gene therapy manufacturing capabilities form the cornerstone of Biogen’s long-term value proposition”

Fein also asserted that his firm elects “to focus on the prospects of the AD franchise with aducanumab as the leading asset based on the view that it is a major long-term value driver.” Eisai’s opt-in on aducanumab “certainly adds an external validation for the program as well,” the analyst added.

Fein commented on Biogen’s other Alzheimer’s assets as well, asserting, “While investors may remain cautious of aducanumab as the depressed outlook for Abeta thesis remains, largely due to the misses of several high-profile Phase 3 trials by targeting Abeta, we highlight the company’s robust AD pipeline. Beyond two anti-Abeta antibodies, namely aducanumab (in Phase 3) and BAN2401 (in Phase 2), the company has assets targeting BACE1 (Elenbecestat) and tau (BIIB092, BIIB076, BIIB080), two of the most promising therapeutic approaches.”

Biogen’s plans for expanding its reach in neuroscience, including development of therapies for pain and epilepsy, also garnered Fein’s attention. “[The expanding] neurology pipeline reaffirms our belief in [the] company’s core competence of de-risking,” the analyst wrote. “We believe that through the company’s improved translational capabilities, the probability of success across neuroscience should be enhanced, and we view these capabilities as the company’s ultimate value driver of future growth.”

Want to read more Life Sciences Report articles like this? Sign up at www.streetwisereports.com/get-news for our free e-newsletter, and you’ll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Additional disclosures about the sources cited in this article

( Companies Mentioned: BIIB:NASDAQ,
)